Skip to content
Ejaculation.org

Case series · 2016

Cabergoline in the Treatment of Male Orgasmic Disorder: A Retrospective Pilot Analysis

Hollander AB, Pastuszak AW, Hsieh TC, Johnson WG, Scovell JM, Mai CK, Lipshultz LI (2016). Cabergoline in the Treatment of Male Orgasmic Disorder: A Retrospective Pilot Analysis. Sexual Medicine. doi:10.1016/j.esxm.2015.09.001

Key finding
In a retrospective chart review of 131 men treated at one andrology clinic for delayed orgasm or anorgasmia with cabergoline 0.5 mg twice weekly, 87 (66.4%) reported subjective improvement in orgasm and 44 (33.6%) no change.

Summary

Cabergoline is a dopamine agonist, a drug that acts in the brain and lowers the hormone prolactin. This US study reviewed the records of men treated at a single andrology clinic for delayed orgasm or anorgasmia (being unable to reach orgasm) who had been given cabergoline 0.5 mg twice a week.

Of 131 men, 87 (66.4%) reported a subjective improvement in orgasm and 44 (33.6%) reported no change. A longer duration of treatment and taking testosterone therapy at the same time were linked with a better response. Age and previous prostate removal did not affect the outcome. The authors call for prospective randomised trials to establish cabergoline's true role.

Limitations

This is a retrospective review of clinic records with no placebo group, so part of the improvement may reflect expectation, time or other treatments. The outcome was the man's own impression, not a validated measure, and the study was carried out at a single specialist clinic.

What it means for you

Cabergoline is one of the medicines specialists sometimes prescribe off-label for delayed orgasm or ejaculation, but the evidence is early. It is a question to discuss with a urologist or andrologist, not a drug to source yourself.